Study termination due to negative Phase III of another study product from same technology platform.

This study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.

Inclusion Criteria:

• The patient has 18 years of age or older at the time of consent.
• The patient has provided pre-treatment tumor samples for WT1 expression screening and gene expression profiling in the context of the NCT01220128 study.
• The patient has a histologically or cytologically confirmed primary invasive breast cancer.
• The patient has provided written informed consent before any new information or new material is provided to the Sponsor.
• The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.
• The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.

Exclusion Criteria:

Not applicable.

Patients who provided a pretreatment tumor sample for Wilms' Tumor 1 (WT1) expression screening in the context of a neoadjuvant interventional study (111172 (WT1-AS15-BRS-001 (NEOADJ)), but who were not included into the active phase of this study.